(CPIX) Cumberland Pharmaceuticals - Ratings and Ratios

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) is a specialty pharmaceutical company focused on the development, acquisition, and commercialization of prescription products for critical care, gastroenterology, and oncology. The company specializes in high-value, niche therapies addressing unmet medical needs in both inpatient and outpatient settings. Its product portfolio includes Acetadote for acetaminophen poisoning, Caldolor for pain and fever, Kristalose for constipation, Omeclamox-Pak for H. pylori infections, Vaprisol for hyponatremia, Sancuso for chemotherapy-induced nausea, and Vibativ for serious bacterial infections. The pipeline includes RediTrex for rheumatoid and psoriatic conditions, and ifetroban, currently in Phase II for multiple indications, including aspirin-exacerbated respiratory disease and Duchenne muscular dystrophy. The company has also completed Phase II trials for hepatorenal syndrome and is exploring ifetroban for progressive fibrosing interstitial lung diseases.

Founded in 1999 and headquartered in Nashville, Tennessee, Cumberland Pharmaceuticals operates with a market capitalization of $68.25M. The stock has shown volatility, with a 20-day average volume of 3.5M shares. Recent price action indicates a potential bullish crossover, with the 20-day SMA ($5.21) rising above the 50-day SMA ($3.55). The ATR of $0.63 reflects moderate price movement. The P/S ratio of 1.86 suggests a reasonable valuation relative to sales, while the P/B ratio of 2.76 indicates assets are valued higher than book value. However, the negative RoE of -43.86% highlights profitability challenges.

Based on technical and fundamental data, Cumberland Pharmaceuticals Inc. (CPIX) is expected to experience continued volatility over the next three months. The stock may test resistance near $6.50, supported by the rising 20-day SMA. The 50-day SMA ($3.55) and 200-day SMA ($1.93) suggest long-term upside potential but indicate caution due to negative earnings. The ATR of $0.63 predicts moderate price swings. Fundamentally, the companys focus on niche therapies and pipeline progress may support investor sentiment, though profitability concerns persist. Expect a sideways to slightly upward trend in the near term, contingent on clinical trial outcomes and revenue growth.